Nuvation Bio reports Q4 2022 net loss $20.8M, cash $661M; advances NUV-868 and DDC

Nuvation Bio Inc.

Net loss Q4 2022 $20.8M ($0.10/sh) vs $25.1M ($0.12/sh) Q4 2021; full-year net loss $104.2M.
Cash, equivalents and marketable securities $661.0M as of Dec 31, 2022; no debt disclosed.
R&D expense Q4 2022 $16.9M (down from $22.0M); G&A $7.4M (vs $7.6M) YoY.
Dosed first patient in Phase 1b combo study of NUV-868 with olaparib or enzalutamide; Phase 1 monotherapy ongoing.
Nominated first DDC clinical candidate; expects IND submission by end of 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Nuvation Bio Inc. reported the fourth quarter and full year ended December 31, 2022 results: net income a net loss of $20.8 million, or $(0.10) per share, EPS $(0.10) per share.

Period: the fourth quarter and full year ended December 31, 2022
Net income: a net loss of $20.8 million, or $(0.10) per share
EPS: $(0.10) per share
Result: reported results

Exact text from the filing

On March 15, 2023, Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ended December 31, 2022.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Nuvation Bio Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-071350

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.